EnLiSense
En Li Sense stands at the forefront of medical innovation, spearheading the development of advanced sweat sensor technology for real-time, non-invasive monitoring. Their offerings include both a first-of-its-kind device and an advanced data and AI platform, blending cutting-edge hardware with sophisticated analytics. Their flagship products, IBD Aware and Corti, are not just wearables; they are gateways to a new era in personalized healthcare. These devices cater to a wide range of use cases, profoundly resonating with both clinicians and patients. They facilitate proactive chronic disease management in conditions like inflammatory bowel disease (IBD) and stress-related disorders, offering clinicians and patients unprecedented insights into both physiological and disease states for treatment timing and effectiveness, symptom management, and dietary and lifestyle adjustments – aspects previously inaccessible in real-time. The technology is validated to continuously monitor a comprehensive range of biomarkers including Calprotectin, CRP, TNF-Alpha, IL-6, Cortisol, Melatonin, Glucose, and many others, transforming how healthcare professionals and patients approach treatment and management. The journey of En Li Sense is characterized by a relentless pursuit of elevating the standard of care through continuous innovation. Their solutions are designed not only to meet current healthcare challenges but also to anticipate future needs. En Li Sense continues to expand research and development efforts into new biomarkers and disease applications, broadening the scope of the technology platform to encompass a wider spectrum of chronic conditions. This expansion is underpinned by a commitment to cost-effective, precision medicine, ensuring that each advancement brings us closer to a future where healthcare is more personalized, proactive, and patient-centered.
EnLiSense
En Li Sense stands at the forefront of medical innovation, spearheading the development of advanced sweat sensor technology for real-time, non-invasive monitoring. Their offerings include both a first-of-its-kind device and an advanced data and AI platform, blending cutting-edge hardware with sophisticated analytics. Their flagship products, IBD Aware and Corti, are not just wearables; they are gateways to a new era in personalized healthcare. These devices cater to a wide range of use cases, profoundly resonating with both clinicians and patients. They facilitate proactive chronic disease management in conditions like inflammatory bowel disease (IBD) and stress-related disorders, offering clinicians and patients unprecedented insights into both physiological and disease states for treatment timing and effectiveness, symptom management, and dietary and lifestyle adjustments – aspects previously inaccessible in real-time. The technology is validated to continuously monitor a comprehensive range of biomarkers including Calprotectin, CRP, TNF-Alpha, IL-6, Cortisol, Melatonin, Glucose, and many others, transforming how healthcare professionals and patients approach treatment and management. The journey of En Li Sense is characterized by a relentless pursuit of elevating the standard of care through continuous innovation. Their solutions are designed not only to meet current healthcare challenges but also to anticipate future needs. En Li Sense continues to expand research and development efforts into new biomarkers and disease applications, broadening the scope of the technology platform to encompass a wider spectrum of chronic conditions. This expansion is underpinned by a commitment to cost-effective, precision medicine, ensuring that each advancement brings us closer to a future where healthcare is more personalized, proactive, and patient-centered.
TL;DR
Headquarters: Allen, Texas, United States
Product: Non-invasive wearable biosensors and data/AI platform (e.g., IBD Aware, Corti, Sweat Aware)
Use cases: Real-time biomarker monitoring for chronic disease management and wellness
Funding signal: Grant from Crohn's & Colitis Foundation (Mar 21, 2023)
Company Overview
Problem Domain
Non-invasive real-time biomarker monitoring for chronic disease management and wellness.
Industry
Medtech / Biosensors
Funding Track Record
Grant announced to support development of a real-time inflammation monitor for IBD
Investor Signal
“Grant funding from Crohn's & Colitis Foundation indicates targeted disease-focused research support”